ESMO 2017 | Rucaparib and ARIEL3 – positive results from the Phase 3 trial in ovarian cancer patients

Jonathan Ledermann, BSc, MD, FRCP, from University College London, London, UK, gives us a comprehensive overview of the ARIEL 3 trial of rucaparib in patients with recurrent ovarian cancer. He describes the rationale behind the study, its design and the positive results. Watch the video recorded at the European Society for Medical Oncology (ESMO) 2017 Congress to get Jonathan’s thoughts on what this means for the ongoing treatment of patients with the disease.